eyenovia-logo 3

Investor Relations

Investor Relations

Corporate Profile

Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed indications for presbyopia, myopia progression and mydriasis.

Presentation & Investor Materials

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News Releases
03/23/23
Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30
02/28/23
Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House’s Office of Public Engagement
02/15/23
Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals
Upcoming Events
Date Title
Thursday, March 30, 2023 4:30 PM EDT